Connect with us

Technology

LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and Expedite Vaccine Production

Published

on

Advancing CEPI’s 100 Days Mission to Accelerate Vaccine Development

DUSSELDORF, Germany, Oct. 2, 2024 /PRNewswire/ — LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale up protein manufacturing capabilities and expedite vaccine production.

This collaboration is part of the expansion in scope of LenioBio’s CEPI-funded project, which aims to showcase the capacity and speed of LenioBio’s proprietary ALiCE® protein expression technology to accelerate production of vaccine-relevant proteins for use in clinical trials. This project fully aligns with the 100 Days Mission spearheaded by CEPI.

The project extension follows a successful first six months during which LenioBio achieved all key milestones. They successfully demonstrated  ALiCE®’s ability to reliably produce vaccine-relevant proteins at small scales from cell-free DNA formats, and developed a suite of novel quality control assays to ensure the highest standards of product integrity and safety throughout the protein production process.

Building on this success, LenioBio will be collaborating with ReciBioPharm to achieve scaled production of vaccine proteins using ALiCE®. ReciBioPharm’s expertise in process development and manufacturing of complex biologics, along with its global footprint, will be instrumental in unlocking the full potential of ALiCE® for vaccine manufacturing and pave the path towards future GMP applications.

“Being involved in the 100 Days Mission is both an honor and a significant responsibility,” said André Goerke, CEO of LenioBio. “Our collaboration with ReciBioPharm brings us one step closer to making the vision of rapid vaccine development a reality. By transferring protein production with ALiCE® to a leading CDMO, we aim to meet the urgent need for swift vaccine production, crucial for containing emerging health threats.”

The newly announced collaboration will include technology transfer for 10-liter scale protein production of a vaccine candidate, using ALiCE®- including both upstream and downstream unit operations – to ReciBiopharm’ site in Oeiras, Portugal. This process will involve initial process and analytical method transfer and will deliver material to be used in pre-clinical studies. Establishing the ALiCE® technology in a scaled manufacturing environment is a critical first step in a roadmap toward GMP and the production of material for clinical trials and vaccine manufacture.

Vikas Gupta, president, ReciBioPharm, said: “Our collaboration with LenioBio represents a significant step forward in recombinant protein manufacturing. LenioBio’s ALiCE® technology is well-positioned to make a meaningful impact on global health, and accelerate the development of vaccines and other critical biologics. ReciBioPharm is glad to play a crucial role in proving LenioBio’s innovative platform at-scale and look forward a future where such technology will be used in clinical trials. This partnership perfectly aligns with our commitment to innovation. We are making the vision of a future where vaccines can be developed and deployed more rapidly in response to emerging threats, a reality.”

Looking ahead, LenioBio plans to conduct in-depth evaluations of ALiCE®-produced protein quality through in vivo studies focusing on dosage and efficacy. The company also intends to engage in further regulatory discussions to position ALiCE® as a platform technology for expedited development of protein medicines, aiming to reduce the time it takes for vaccines and therapeutics to reach clinical trials.

The 100 Days Mission:

The 100 Days Mission, spearheaded by CEPI and embraced by global leaders in the G7 and G20, seeks to dramatically shorten the vaccine development timeline. By reducing the time it took to develop the first licensed COVID-19 vaccines by two-thirds, this initiative has the potential to prevent future epidemics from escalating into pandemics.

About LenioBio

LenioBio is a life sciences biotech company, pioneering a disruptive protein expression platform. Using ALiCE® technology, enabling customers – researchers and biopharma manufacturers to streamline and accelerate their protein discovery, development, and production processes. LenioBio simplifies manufacturing and speeds up the delivery of drugs to the patients.

About ReciBioPharm

ReciBioPharm, a division of Recipharm, is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specialized CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Led by a management team and technical experts with a proven track record in both process development and contract manufacturing, ReciBioPharm offers the knowledge and resources necessary to help customers develop and manufacture promising new therapies to meet the needs of patients across the world.

Logo – https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/leniobio-collaborates-with-recibiopharm-to-scale-up-alice-technology-and-expedite-vaccine-production-302264458.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Greenzie releases 2025 Annual Safety Report, documenting multi-year safety performance at commercial scale

Published

on

By

The data shows zero lost-time injuries, zero OSHA medical attentions and zero human near-misses across real-world operation

ATLANTA, April 23, 2026 /PRNewswire/ — Greenzie, the technology platform powering commercial autonomy across multiple OEMs, today shared multi-year safety data from real-world commercial operation, documenting more than 150,000 autonomous miles with zero lost-time injuries, zero OSHA medical attentions and zero human near-misses. The data is published in Greenzie’s 2025 Annual Safety Report, available at greenzie.com/safety.

The report is based on extensive operational data spanning more than 5.4 billion square feet of turf mowed, 68,000+ hours of autonomous mowing and more than 50,000 operator days, the equivalent of 265 mowing seasons.

“Greenzie is helping define safety in autonomous landscape operations, and transparency is a critical part of that,” said Steve Bush, chief operating officer of Greenzie. “These results show that commercial autonomy is operating safely at meaningful scale in the field. Transparency matters because as this category matures, real-world data helps build confidence in what responsible deployment looks like.”

The report’s findings are particularly significant in the context of the U.S. landscaping industry, which employs roughly 1.3 million workers and experiences a higher-than-average rate of workplace accidents compared to other fields. Greenzie’s multi-year operating data shows that autonomy is not theoretical; it is already being deployed consistently and performing safely at scale.

“Greenzie Powered Autonomy™ has been validated through years of sustained use in the field,” Bush said. “That level of real-world performance reinforces both the reliability of our platform and the broader readiness of commercial autonomy.”

Greenzie attributes this performance to a disciplined safety approach that includes robust perception, tested operating standards and continuous validation in real-world commercial environments.

For more information about Greenzie, visit greenzie.com.

About Greenzie

Founded in 2018, Greenzie is the technology platform powering commercial autonomy. Created to solve the landscape industry’s labor and productivity challenges, Greenzie works with leading equipment manufacturers to deliver the software, navigation and safety systems that enable mowing and other outdoor power equipment to operate autonomously in real-world commercial environments. Today, Greenzie’s platform is running on hundreds of machines in active use, helping manufacturers bring autonomy to market and allowing operators to get more done with limited labor—moving autonomy from early experimentation to everyday operations. For more information, visit greenzie.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenzie-releases-2025-annual-safety-report-documenting-multi-year-safety-performance-at-commercial-scale-302750335.html

SOURCE Greenzie

Continue Reading

Technology

CGI renews global SAP S/4HANA operations and SAP BTP operations certifications, reinforcing its consistent, quality delivery at scale

Published

on

By

Stock Market Symbols
GIB.A (TSX)
GIB (NYSE)
cgi.com/newsroom

MONTRÉAL, April 23, 2026 /CNW/ – CGI (NYSE: GIB) (TSX: GIB.A), one of the largest independent IT and business consulting services firms in the world, announced that it has achieved the following recertifications for its global operation capabilities:

SAP S/4HANA operations and works with RISE with SAP SAP BTP operations and works with RISE with SAP

These recertifications highlight CGI’s ability to deliver consistent, high-quality managed SAP services and operations across regions, including services aligned with RISE with SAP. CGI’s SAP-based services help clients reduce operational risk, improve performance and efficiency and scale transformation with greater predictability. This also builds on CGI’s SAP alliance relationship momentum, including its recent AWS SAP Competency Partner status which highlights CGI’s expertise in modernizing mission-critical SAP workloads with AI-enabled cloud solutions.

“Running SAP at enterprise scale requires a partner with proven capabilities, delivery discipline and the ability to innovate securely, including through the integration of AI to deliver tangible outcomes,” said Didier Thérond, President, CGI France operations, and Global Executive Sponsor for CGI’s partnership with SAP. “These global recertifications reinforce CGI’s end-to-end SAP capabilities, including AI-enabled services, helping clients operate mission-critical systems with confidence and advance their modernization and cloud strategies.”

“CGI remains a trusted partner in our SAP Operations Partner program, consistently demonstrating a structured and disciplined approach to certification,” said Rudolf Scheipers, VP, Head of SAP Operations Partner Certification, SAP Partner Innovation Lifecycle Services. “These recertifications highlight the company’s mature operating model and commitment to the high standards we expect globally, ensuring clients running SAP environments can rely on consistent, secure, and efficient operations.”

CGI’s global alliance strategy features partnerships with more than 150 technology companies and supports its local relationship model complemented by a global delivery network. Through its SAP alliance, CGI helps organizations accelerate innovation, deploy and manage SAP solutions globally, and deliver industry-specific business outcomes with rapid, scalable, and AI-enabled cloud and ERP services.

About CGI
Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 94,000 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2025 reported revenue is CA$15.91 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com.

View original content:https://www.prnewswire.com/news-releases/cgi-renews-global-sap-s4hana-operations-and-sap-btp-operations-certifications-reinforcing-its-consistent-quality-delivery-at-scale-302750863.html

SOURCE CGI Inc.

Continue Reading

Technology

Scholastic Corporation Announces Final Results of Modified Dutch Auction Tender Offer

Published

on

By

NEW YORK, April 23, 2026 /PRNewswire/ — Scholastic Corporation (the “Company” or “Scholastic”) (Nasdaq: SCHL), the global children’s publishing, education and media company, today announced the final results of its “modified Dutch Auction” tender offer for shares of its common stock, which expired at 5:00 p.m., New York City time, on April 20, 2026.

Based on the final count by Computershare Trust Company, N.A., the depositary for the tender offer, a total of 2,834,018 shares of Scholastic’s common stock, par value $0.01 per share (each share of Scholastic’s common stock, a “Share,” and collectively, “Shares”), were properly tendered and not properly withdrawn at or below the purchase price of $40.00 per Share, including 989,343 Shares that were tendered by notice of guaranteed delivery.

Scholastic has accepted for purchase a total of 2,834,018 Shares through the tender offer at a price of $40.00 per Share, for an aggregate cost of $113,360,720.00, excluding fees and expenses relating to the tender offer.  The total of 2,834,018 Shares that Scholastic has accepted for purchase represents approximately 13.7% of the total number of Shares outstanding as of April 19,  2026.

J.P. Morgan Securities LLC served as the dealer manager for the tender offer. Georgeson LLC served as the information agent. Holders of common stock who have questions or need information about the tender offer may call Georgeson LLC at (866) 539-9980 (toll free). Banks and brokers may call Georgeson at (866) 539-9980 or J.P. Morgan Securities LLC at (877) 371-5947 (toll free).

About Scholastic 

For more than 100 years, Scholastic Corporation (Nasdaq: SCHL) has been meeting children where they are – at school, at home and in their communities – by creating quality content and experiences, all beginning with literacy. Scholastic delivers stories, characters, and learning moments that empower all kids to become lifelong readers and learners through bestselling children’s books, literacy- and knowledge-building resources for schools including classroom magazines, and award-winning, entertaining children’s media. As the world’s largest publisher and distributor of children’s books through school-based book clubs and book fairs, classroom libraries, school and public libraries, retail, and online, and with a global reach into more than 135 countries, Scholastic encourages the personal and intellectual growth of all children, while nurturing a lifelong relationship with reading, themselves, and the world around them. Learn more at www.scholastic.com.

Forward-Looking Statements

This news release contains certain forward-looking statements. Such forward-looking statements are subject to various risks and uncertainties, including the conditions of the children’s book and educational materials markets generally and acceptance of the Company’s products within those markets, and other risks and factors identified from time to time in the Company’s filings with the Securities and Exchange Commission. Actual results could differ materially from those currently anticipated.

SCHL: Financial

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/scholastic-corporation-announces-final-results-of-modified-dutch-auction-tender-offer-302751142.html

SOURCE Scholastic Corporation

Continue Reading

Trending